Literature DB >> 26002543

Serotonin abnormalities in Engrailed-2 knockout mice: New insight relevant for a model of Autism Spectrum Disorder.

Cristina Viaggi1, Claudio Gerace1, Carla Pardini1, Giovanni U Corsini1, Francesca Vaglini2.   

Abstract

Autism spectrum disorder (ASD) is a congenital neurodevelopmental behavioral disorder that appears in early childhood. Recent human genetic studies identified the homeobox transcription factor, Engrailed 2 (EN2), as a possible ASD susceptibility gene. En2 knockout mice (En2-/-) display subtle cerebellar neuropathological changes and reduced levels of tyrosine hydroxylase, noradrenaline and serotonin in the hippocampus and cerebral cortex similar to those ones which have been observed in the ASD brain. Furthermore other similarities link En2 knockout mice to ASD patients. Several lines of evidence suggest that serotonin may play an important role in the pathophysiology of the disease. In the present study we measured, by using an HPLC, the 5-HT levels in different brain areas and at different ages in En2-/- mice. In the frontal and occipital cortex, the content of 5HT was reduced in En2-/- 1 and 3 months old mice; in 6 month old mice, the difference was still present, but it was not statistically significant. The 5-HT content of cerebellar cortex was significantly reduced at 1 month old but significantly high when the KO mice reached 3 months of age. The increase was present even at 6 months of age. A similar trend was highlighted by SERT immunolabeling in En2-/- mice compared to control in the same areas and age analyzed. Our findings, in agreement with the current knowledge on the 5-HT system alterations in ASD, confirm the early neurotransmitter deficit with a late compensatory recovery in En2 KO-mice further suggesting that this experimental animal may be considered a good predictive model for the human disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal model; Autism spectrum disorder; Cerebellum; Engrailed 2; Serotonin

Mesh:

Substances:

Year:  2015        PMID: 26002543     DOI: 10.1016/j.neuint.2015.05.004

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

1.  Hsa-miR-27b is up-regulated in cytomegalovirus-infected human glioma cells, targets engrailed-2 and inhibits its expression.

Authors:  Linqian Wang; Ming Yang; Shijing Liao; Wei Liu; Gan Dai; Guojun Wu; Liyu Chen
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-26

2.  What Gene Mutations Affect Serotonin in Mice?

Authors:  Richard C Tenpenny; Kathryn G Commons
Journal:  ACS Chem Neurosci       Date:  2017-04-27       Impact factor: 4.418

Review 3.  Serotonin neuron development: shaping molecular and structural identities.

Authors:  Evan Deneris; Patricia Gaspar
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2017-10-26       Impact factor: 5.814

Review 4.  5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy.

Authors:  Hongyan Zhao; Yang Lin; Shurui Chen; Xin Li; Hongliang Huo
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

5.  Morphological alterations of the reticular thalamic nucleus in Engrailed-2 knockout mice.

Authors:  Andrea Pirone; Cristina Viaggi; Carlo Cantile; Elisabetta Giannessi; Carla Pardini; Francesca Vaglini; Vincenzo Miragliotta
Journal:  J Anat       Date:  2020-01-23       Impact factor: 2.610

6.  Comparative Gene Expression Analysis of Two Mouse Models of Autism: Transcriptome Profiling of the BTBR and En2 (-/-) Hippocampus.

Authors:  Giovanni Provenzano; Zelia Corradi; Katia Monsorno; Tarcisio Fedrizzi; Laura Ricceri; Maria L Scattoni; Yuri Bozzi
Journal:  Front Neurosci       Date:  2016-08-25       Impact factor: 4.677

7.  Clinical Phenotypes Associated to Engrailed 2 Gene Alterations in a Series of Neuropediatric Patients.

Authors:  Francisco Carratala-Marco; Patricia Andreo-Lillo; Marta Martinez-Morga; Teresa Escamez-Martínez; Arancha Botella-López; Carlos Bueno; Salvador Martinez
Journal:  Front Neuroanat       Date:  2018-08-10       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.